PortalPublikationenAnalysis of tumor antigen-specific T cells and antibodies in...

Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation

Standard

Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. / Widenmeyer, Melanie; Shebzukhov, Yuriy; Haen, Sebastian P; Schmidt, Diethard; Clasen, Stephan; Boss, Andreas; Kuprash, Dmitri V; Nedospasov, Sergei A; Stenzl, Arnulf; Aebert, Hermann; Wernet, Dorothee; Stevanović, Stefan; Pereira, Philippe L; Rammensee, Hans-Georg; Gouttefangeas, Cécile.

in: INT J CANCER, Jahrgang 128, Nr. 11, 01.06.2011, S. 2653-62.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Widenmeyer, M, Shebzukhov, Y, Haen, SP, Schmidt, D, Clasen, S, Boss, A, Kuprash, DV, Nedospasov, SA, Stenzl, A, Aebert, H, Wernet, D, Stevanović, S, Pereira, PL, Rammensee, H-G & Gouttefangeas, C 2011, 'Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation', INT J CANCER, Jg. 128, Nr. 11, S. 2653-62. https://doi.org/10.1002/ijc.25601

APA

Widenmeyer, M., Shebzukhov, Y., Haen, S. P., Schmidt, D., Clasen, S., Boss, A., Kuprash, D. V., Nedospasov, S. A., Stenzl, A., Aebert, H., Wernet, D., Stevanović, S., Pereira, P. L., Rammensee, H-G., & Gouttefangeas, C. (2011). Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. INT J CANCER, 128(11), 2653-62. https://doi.org/10.1002/ijc.25601

Vancouver

Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A et al. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. INT J CANCER. 2011 Jun 1;128(11):2653-62. https://doi.org/10.1002/ijc.25601

Bibtex

@article{ea4ec0bdb04e499e9dd32142ec85e8b8,
title = "Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation",
abstract = "Radiofrequency (RF) ablation is a minimally invasive technique routinely applied for the treatment of primary and secondary liver tumors. It induces cell death by thermal coagulative necrosis of tumor tissues, whereas cellular metabolism can still take place in a transition zone surrounding the necrotic area. An increase in heat shock protein expression occurs shortly after treatment, suggesting that the induction of activating signals may stimulate the host immune system. In addition, various effects on immune effectors have also been observed, including stimulation of tumor-directed T lymphocytes. Here, we prospectively assessed the activation of tumor antigen-specific antibodies, as well as antigen-specific CD4(+) and CD8(+) T cells in patients suffering from primary or secondary malignancies and treated by RF ablation with or without concomitant chemotherapy. An increase of antibodies (in 4 patients of 49), CD4(+) T cells or CD8(+) T cells (in 2 patients of 49) could be detected several weeks to months following intervention. These findings suggest that in addition to the local control of tumor growth, RF ablation can provide the appropriate conditions for activating tumor-antigen specific immune responses.",
keywords = "Aged, Antibodies, Neoplasm/immunology, Antigens, Neoplasm/immunology, CD4-Positive T-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/immunology, Catheter Ablation, Female, Humans, Middle Aged, Neoplasms/immunology, Prognosis, Prospective Studies",
author = "Melanie Widenmeyer and Yuriy Shebzukhov and Haen, {Sebastian P} and Diethard Schmidt and Stephan Clasen and Andreas Boss and Kuprash, {Dmitri V} and Nedospasov, {Sergei A} and Arnulf Stenzl and Hermann Aebert and Dorothee Wernet and Stefan Stevanovi{\'c} and Pereira, {Philippe L} and Hans-Georg Rammensee and C{\'e}cile Gouttefangeas",
note = "Copyright {\textcopyright} 2010 UICC.",
year = "2011",
month = jun,
day = "1",
doi = "10.1002/ijc.25601",
language = "English",
volume = "128",
pages = "2653--62",
journal = "INT J CANCER",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "11",

}

RIS

TY - JOUR

T1 - Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation

AU - Widenmeyer, Melanie

AU - Shebzukhov, Yuriy

AU - Haen, Sebastian P

AU - Schmidt, Diethard

AU - Clasen, Stephan

AU - Boss, Andreas

AU - Kuprash, Dmitri V

AU - Nedospasov, Sergei A

AU - Stenzl, Arnulf

AU - Aebert, Hermann

AU - Wernet, Dorothee

AU - Stevanović, Stefan

AU - Pereira, Philippe L

AU - Rammensee, Hans-Georg

AU - Gouttefangeas, Cécile

N1 - Copyright © 2010 UICC.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Radiofrequency (RF) ablation is a minimally invasive technique routinely applied for the treatment of primary and secondary liver tumors. It induces cell death by thermal coagulative necrosis of tumor tissues, whereas cellular metabolism can still take place in a transition zone surrounding the necrotic area. An increase in heat shock protein expression occurs shortly after treatment, suggesting that the induction of activating signals may stimulate the host immune system. In addition, various effects on immune effectors have also been observed, including stimulation of tumor-directed T lymphocytes. Here, we prospectively assessed the activation of tumor antigen-specific antibodies, as well as antigen-specific CD4(+) and CD8(+) T cells in patients suffering from primary or secondary malignancies and treated by RF ablation with or without concomitant chemotherapy. An increase of antibodies (in 4 patients of 49), CD4(+) T cells or CD8(+) T cells (in 2 patients of 49) could be detected several weeks to months following intervention. These findings suggest that in addition to the local control of tumor growth, RF ablation can provide the appropriate conditions for activating tumor-antigen specific immune responses.

AB - Radiofrequency (RF) ablation is a minimally invasive technique routinely applied for the treatment of primary and secondary liver tumors. It induces cell death by thermal coagulative necrosis of tumor tissues, whereas cellular metabolism can still take place in a transition zone surrounding the necrotic area. An increase in heat shock protein expression occurs shortly after treatment, suggesting that the induction of activating signals may stimulate the host immune system. In addition, various effects on immune effectors have also been observed, including stimulation of tumor-directed T lymphocytes. Here, we prospectively assessed the activation of tumor antigen-specific antibodies, as well as antigen-specific CD4(+) and CD8(+) T cells in patients suffering from primary or secondary malignancies and treated by RF ablation with or without concomitant chemotherapy. An increase of antibodies (in 4 patients of 49), CD4(+) T cells or CD8(+) T cells (in 2 patients of 49) could be detected several weeks to months following intervention. These findings suggest that in addition to the local control of tumor growth, RF ablation can provide the appropriate conditions for activating tumor-antigen specific immune responses.

KW - Aged

KW - Antibodies, Neoplasm/immunology

KW - Antigens, Neoplasm/immunology

KW - CD4-Positive T-Lymphocytes/immunology

KW - CD8-Positive T-Lymphocytes/immunology

KW - Catheter Ablation

KW - Female

KW - Humans

KW - Middle Aged

KW - Neoplasms/immunology

KW - Prognosis

KW - Prospective Studies

U2 - 10.1002/ijc.25601

DO - 10.1002/ijc.25601

M3 - SCORING: Journal article

C2 - 20715115

VL - 128

SP - 2653

EP - 2662

JO - INT J CANCER

JF - INT J CANCER

SN - 0020-7136

IS - 11

ER -